Literature DB >> 10855970

Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases.

K E Goeringer1, L Raymon, G D Christian, B K Logan.   

Abstract

This paper reviews the complex pharmacology of the new class of antidepressant medications exhibiting selective inhibition of serotonin reuptake. The four selective serotonin reuptake inhibitors (SSRIs) considered--fluoxetine, fluvoxamine, sertraline and paroxetine--can result in toxicity and death through contributing to serotonergic excess resulting in serotonin syndrome, inhibiting the metabolism of other centrally acting drugs, leading to accumulation of toxic concentrations, and exerting complex vasoactive effects on the vascular smooth muscle. This latter feature is of particular concern in patients with preexisting heart disease. An analytical method involving isolation of the drugs by liquid/liquid extraction at alkaline pH into n-butyl chloride, and analysis by gas chromatography/mass spectrometry (GC/MS) is described, together with some of its limitations. Toxicologic and cause and manner of death data were examined in 60 deaths involving fluoxetine, 5 involving fluvoxamine, 75 involving sertraline, and 28 involving paroxetine. Deaths involving drug toxicity were generally a result of ingestion of multiple drugs, and in only a small number of the cases was death attributed principally to the SSRI involved. The potential for drug interactions between members of this class of drugs is discussed as well as their metabolites and a variety of other therapeutic and abused drugs which can contribute to their toxicity. In the absence of other risk factors, the lowest concentrations determined to have resulted in death were 0.63 mg/L for fluoxetine, 0.4 mg/L for paroxetine, and 1.5 mg/L for sertraline. We had insufficient data to make even this crude assessment for fluvoxamine. Drug-induced elevation of serotonin concentrations may be a significant risk factor for patients with atherosclerotic cardiovascular disease (ASCVD). Other factors including preexisting disease and the presence of other drugs and their pharmacology need to be carefully considered before determining the appropriate cause and manner of death in these cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10855970

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  6 in total

1.  Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.

Authors:  Sarah M R Wille; Els A De Letter; Michel H A Piette; Lien K Van Overschelde; Carlos H Van Peteghem; Willy E Lambert
Journal:  Int J Legal Med       Date:  2008-10-07       Impact factor: 2.686

Review 2.  The influence of putrefaction and sample storage on post-mortem toxicology results.

Authors:  Danielle M Butzbach
Journal:  Forensic Sci Med Pathol       Date:  2009-11-28       Impact factor: 2.007

Review 3.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Paroxetine overdose.

Authors:  Arun K Gupta; Pankaj Verma; Samir K Praharaj; Dipayan Roy; Anuradha Singh
Journal:  Indian J Psychiatry       Date:  2005-07       Impact factor: 1.759

5.  Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.